Posted by Michael Wonder on 24 Nov 2020
New option for people with difficult-to-treat multiple myeloma is recommended for use in Cancer Drugs Fund by NICE
24 November 2020 - Around 5,700 cases of multiple myeloma are diagnosed each year in the UK.
Isatuximab, administered as an intravenous infusion, plus pomalidomide and dexamethasone is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults.
